Sermorelin and Tesamorelin both act on the same GHRH receptor, but Tesamorelin is more clinically validated for the visceral-fat-reduction indication and produces more consistent reductions in deep abdominal fat in studies
Oxidatively generated damage to cellular DNA by UVB and UVA radiation
Clinical Trial Outcomes with Monotherapy The REDEFINE 1 trial demonstrated that cagrilintide monotherapy at the 4.5 mg maintenance dose produced mean body weight reductions of approximately 10.8% from baseline after 32 weeks of treatment [4]
Most providers restart semaglutide at 0.5 mg or 1.0 mg depending on what tirzepatide dose you were taking, then titrate based on response
Zhu CH, Huang Y, Oberley LW, Domann FE
Finally, patients unwilling or unable to commit to regular self-injection (for injectable formulations) or daily oral dosing should discuss alternative weight loss strategies with their healthcare provider